MRK
DisruptorMerck & Co.
$120.15
-1.05%
as of 13 Apr
Power Core
Merck's moat is the deepest clinical dataset and broadest label footprint in checkpoint inhibitor oncology, embedded into treatment guidelines across more than 40 tumor types worldwide.
Direction of Movement
Lateral: Defending the Present While Building the Future
ROC 200
+49.3%
MRK
Merck & Co.
$120.15
-1.05%
as of 13 Apr
DCF Fair Value: $158.90
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Merck & Co., Inc. operates as a leading healthcare company worldwide, focusing on human health pharmaceuticals, vaccines, and animal health products. Its portfolio includes blockbuster drugs like Keytruda for immuno-oncology, Gardasil for human papillomavirus prevention, and a range of treatments such as Welireg, ProQuad, Winrevair, Januvia, and others addressing cancer, infectious diseases, cardiometabolic conditions, and more. The company also provides veterinary solutions including Nuflor and Bovilis for livestock health management. With a substantial presence in oncology, its Keytruda leads sales contributions, complemented by vaccines targeting pediatric diseases. Merck & Co., Inc. generates significant revenue—$64.17 billion in 2024—from pharmaceuticals and vaccines, primarily in the U.S., while maintaining a diversified global footprint across consumer, business, and government sectors. Employing around 75,000 people, it plays a pivotal role in advancing treatments for chronic and infectious diseases, driving innovation in biopharmaceuticals and immunotherapy.